文献速递白血病

英国儿童急性淋巴细胞白血病疗效的显著提升:UKALL系列试验与国际合作的成果

Improvements in outcome of childhood acute lymphoblastic leukaemia (ALL) in the UK - a success story of modern medicine through successive UKALL trials and international collaboration.
PubMed 文献 · Br J Haematol · 2020-01-01

UKALL系列试验通过优化治疗分层与方案安排,在不依赖新药的情况下实现了优异疗效,并正与欧洲其他组织合作启动统一方案的ALLTogether协作组。

要点

  • 2020年超过90%的儿童和超过70%的年轻成人ALL患者可通过一线治疗治愈。
  • 20-50%的复发患者可获挽救治疗,比例取决于年龄和复发时机。
  • UKALL试验通过优化治疗分层和方案安排实现了优异疗效,不依赖新药。

主要发现

  • 2020年超过90%的儿童和超过70%的年轻成人ALL患者可通过一线治疗治愈。
  • 20-50%的复发患者可获挽救治疗,比例取决于年龄和复发时机。
  • 治疗重点正逐渐从强化治疗转向使用新药以优化疗效并减少急性和长期毒性。

临床怎么用

  • UKALL试验通过优化治疗分层和方案安排,在不使用新药的情况下实现了优异疗效。
  • 治疗重点逐渐转向使用新药(包括免疫治疗方法)以优化疗效并减少毒性。
  • UKALL与欧洲其他组织合作,基于统一ALL方案(ALLTogether)启动新的协作组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sixty years ago, there was no expectation of cure for children with acute lymphoblastic leukaemia (ALL) and treatment was essentially palliative. In the year 2020, >90% of children and >70% of young adults can expect to be cured with first-line therapy and 20-50% of relapses can be salvaged depending on age and timing of relapse. The focus of treatment is gradually shifting from intensive therapy to the use of new agents to optimise efficacy, while minimising acute and long-term toxicity. The UKALL trials have made important contributions to the refinement of treatment stratification and scheduling, which have delivered the excellent outcomes to date without new agents. This year UKALL, with other groups across Europe, will begin a new collaborative group working from a unified ALL protocol (ALLTogether) that will incorporate new agents including immune-based approaches.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Bartram J, Veys P, Vora A, et al. Improvements in outcome of childhood acute lymphoblastic leukaemia (ALL) in the UK - a success story of modern medicine through successive UKALL trials and international collaboration. Br J Haematol. 2020. PMID: 33190256. doi:10.1111/bjh.17162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。